Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravenous vs. Intracoronary Use of Abciximab.

Trial Profile

Intravenous vs. Intracoronary Use of Abciximab.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abciximab (Primary) ; Abciximab (Primary)
  • Indications Coronary stent thrombosis; Myocardial infarction
  • Focus Therapeutic Use

Most Recent Events

  • 01 Dec 2011 Results published in Cardiology.
  • 09 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 18 Nov 2009 Results presented at the 82nd Annual Scientific Sessions of the American Heart Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top